Analyst Price Targets — MAR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 12, 2026 11:44 am | Stephen Grambling | Morgan Stanley | $384.00 | $365.88 | TheFly | Marriott price target raised to $384 from $380 at Morgan Stanley |
| September 10, 2026 12:04 pm | — | Truist Financial | $360.00 | $332.84 | TheFly | Marriott price target raised to $360 from $356 at Truist |
| August 20, 2026 11:06 am | Robin Farley | UBS | $395.00 | $359.95 | TheFly | Marriott price target lowered to $395 from $412 at UBS |
| August 4, 2026 12:43 pm | — | Deutsche Bank | $372.00 | $344.70 | TheFly | Marriott price target lowered to $372 from $379 at Deutsche Bank |
| August 4, 2026 10:15 am | — | Robert W. Baird | $393.00 | $346.83 | TheFly | Marriott price target lowered to $393 from $394 at Baird |
| August 4, 2026 9:30 am | Brandt Montour | Barclays | $348.00 | $346.83 | TheFly | Marriott price target lowered to $348 from $379 at Barclays |
| August 3, 2026 8:24 pm | — | BMO Capital | $395.00 | $346.83 | TheFly | Marriott price target lowered to $395 from $410 at BMO Capital |
| August 3, 2026 2:48 pm | Simon Yarmak | Stifel Nicolaus | $343.00 | $345.78 | TheFly | Marriott price target lowered to $343 from $365 at Stifel |
| July 20, 2026 10:26 am | — | Barclays | $379.00 | $366.24 | TheFly | Marriott price target raised to $379 from $376 at Barclays |
| July 16, 2026 10:07 am | — | Wells Fargo | $449.00 | $369.05 | TheFly | Marriott price target raised to $449 from $446 at Wells Fargo |
Latest News for MAR
BETHESDA, Md., Oct. 9, 2026 /PRNewswire/ -- Marriott International, Inc. (Nasdaq: MAR) will report third quarter 2026 earnings results on Monday, November 2, 2026, at approximately 7:00 a.m.
Local cuisine emerges as the region's strongest dining force, as traditional restaurant settings give way to fluid, social spaces. SINGAPORE, Oct. 6, 2026 /PRNewswire/ -- Marriott International has unveiled Future of Food 2027, its latest report exploring food and beverage trends across Asia Pacific excluding China.
Refreshed accommodations, light-filled public spaces, and vibrant culinary debuts an enriched resort experience grounded in nature, play, and community. NAPLES, Fla.
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) subsidiary Marea Therapeutics has dosed the first patient in a Phase 2 clinical trial of MAR002, a first-in-class antibody therapy for acromegaly, the company said on Monday. Marea, which is developing medicines for cardioendocrine diseases, is advancing MAR002 as a potential new option for the rare endocrine disorder.
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.